Who
Andrew T. Kaplan
Director and 10% owner
Company insider
Files Form 4 as: Director and 10% owner, Kailera Therapeutics; Director and 10% owner, Surgery Partners.
In numbers
- Trades disclosed
- 10
- Buys
- 1
- Sells
- 1
- Bought
- $268.8M
- Sold
- $261.7M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 19 Dec 2023
- Last trade
- 20 Apr 2026
- Last filed
- 20 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Apr 2026filed 20 Apr 2026 | KLRA Kailera TherapeuticsBiotechnology | SEC FORM 4 Code C | —17,857,143 | filing |
| 20 Apr 2026filed 20 Apr 2026 | KLRA Kailera TherapeuticsBiotechnology | SEC FORM 4 Bought | $134.4M8,398,438 at $16.00 | filing |
| 20 Apr 2026filed 20 Apr 2026 | KLRA Kailera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —17,857,143 at $0.00 | filing |
| 20 Apr 2026filed 20 Apr 2026 | KLRA Kailera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —17,857,143 at $0.00 | filing |
| 20 Apr 2026filed 20 Apr 2026 | KLRA Kailera TherapeuticsBiotechnology | SEC FORM 4 Code C | —17,857,143 | filing |
| 20 Apr 2026filed 20 Apr 2026 | KLRA Kailera TherapeuticsBiotechnology | SEC FORM 4 Bought | $134.4M8,398,438 at $16.00 | filing |
| 16 Apr 2026filed 20 Apr 2026 | KLRA Kailera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,300 at $0.00 | filing |
| 16 Apr 2026filed 20 Apr 2026 | KLRA Kailera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,300 at $0.00 | filing |
| 19 Dec 2023filed 21 Dec 2023 | SGRY Surgery PartnersProviders & Facilities | SEC FORM 4 Sold | $261.7M7,826,870 at $33.44 | filing |
| 19 Dec 2023filed 21 Dec 2023 | SGRY Surgery PartnersProviders & Facilities | SEC FORM 4 Code J | —474,407 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.